home / stock / trypf / trypf news

TRYPF News and Press, Tryp Therapeutics Inc Com

Stock Information
Company Name: Tryp Therapeutics Inc Com
Stock Symbol: TRYPF
Market: OTC
Website: tryptherapeutics.com
Menu
TRYPF TRYPF Quote TRYPF Short TRYPF News TRYPF Articles TRYPF Message Board
Get TRYPF Alerts

News, Short Squeeze, Breakout and More Instantly...
TRYPF - Tryp Therapeutics Files Amended Financial Statements for the Six Months Ended February 29, 2024

Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) (" Tryp " or the " Company ") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the " Financial Statements "), along with the corresponding Manage...
TRYPF - Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement

KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...

TRYPF - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Update on Plan of Arrangement with Exopharm Limited

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...

TRYPF - Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt

KELOWNA, BC / ACCESSWIRE / April 24, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ) is pleased to announce that the shareholders of Exopharm Limited ACN 163 765 991 (" Exopharm ") have approved the previously announced plan of arrangement (the " Arrangemen...
TRYPF - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Shareholders Approve Arrangement Agreement at Annual General and Special Meeting

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that company shareholders approved an announced arrangeme...

TRYPF - Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order

KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ) is pleased to announce that the Company's securityholders overwhelmingly approved the previously announced arrangement (the " Arrangement ") involving the Company and Exoph...

TRYPF - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Interim Order from BC Supreme Court, Plans Meeting of Securityholders

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has obtained an interim order of the Supreme Court of British Colum...
TRYPF - Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting

KELOWNA, BC / ACCESSWIRE / February 8, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet m...

TRYPF - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Exopharm Limited Secure Approval from ASX for 'Pivotal' Two-Cent Waiver

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that it has been granted a pivotal two-cent waiver by the...

TRYPF - Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX

KELOWNA, BC / ACCESSWIRE / January 26, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP )( OTCQB:TRYPF ), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet...
Next 10